O'Hara Elaine
Known title: EVP, Chief Strategy OfficerCIK: 0001968045
Associated companies
Transaction History
| NVAX | ▼ Sell | Tax Withholding | 22,429 | $213K | 3/3/2026 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 56,334 | $0 | 3/3/2026 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 19,600 | $0 | 3/1/2026 | View on chart |
| NVAX | ▼ Sell | Tax Withholding | 5,375 | $55K | 3/1/2026 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 40,000 | $0 | 3/1/2026 | View on chart |
| NVAX | ▼ Sell | Tax Withholding | 10,969 | $111K | 3/1/2026 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 19,600 | $0 | 3/1/2025 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 40,000 | $0 | 3/1/2025 | View on chart |
| NVAX | ▼ Sell | Tax Withholding | 5,375 | $45K | 3/1/2025 | View on chart |
| NVAX | ▼ Sell | Tax Withholding | 10,969 | $91K | 3/1/2025 | View on chart |
| NVAX | ▼ Sell | Tax Withholding | 5,375 | $29K | 3/1/2024 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 19,600 | $106K | 3/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
NVAX Rallies 16% on NIH Cancer Vaccine Push Reports
Novavax shares surged 16% as part of a broader rally in vaccine stocks, driven by reports that the NIH is planning a major push for cancer vaccines. This news lifted the entire sector, with peers like Moderna and Merck also seeing significant gains. The move pushed NVAX into overbought territory, with its RSI reaching 68.6, though it remains below the average analyst target price.
NVAX Rallies 16% on NIH Cancer Vaccine Push Reports. Novavax shares surged 16% as part of a broader rally in vaccine stocks, driven by reports that the NIH is planning a major push for cancer vaccines. This news lifted the entire sector, with peers like Moderna and Merck also seeing significant gains. The move pushed NVAX into overbought territory, with its RSI reaching 68.6, though it remains below the average analyst target price.